Ask AI

Targeting TROP-2 and TIGIT: Experts Discuss How ADCs and Immunotherapeutic Combinations Are Transforming Lung Cancer Treatment

Gain a deeper understanding of the mechanisms of action and rationale for targeting TIGIT and TROP-2 in lung cancer based on recent clinical data and novel targeted therapies to increase clinical trial enrollment and enhance patient outcomes through a certified on-demand webcast, expert-authored ClinicalThought commentary, and accompanying downloadable slides.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.